ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
A Decadal Bibliometric Analysis of Circulating Tumor DNA (ctDNA) Research in Lung Cancer (2012-2022).
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have demonstrated that the plasma level of circulating tumor DNA (ctDNA) has emerged as a highly effective, minimally invasive biomarker in patients with lung cancer. This study aimed to perform bibliometric analysis to systematically evaluate the development trends of ctDNA in lung cancer for future research.
methodsAll articles on the role of ctDNA for detecting lung cancer from January 1, 2012, to December 31, 2022, were retrieved from the Web of Science (WoS) Core Collection database. Data analyses were performed using the R package Bibliometrix, VOS viewer 1.6.18, and online analysis in WoS.
resultsA total of 1122 publications were retrieved: 807 primary articles and 315 review articles. The annual publication volume exhibited a significant upward trajectory, with a Compound Annual Growth Rate (CAGR) of 48.3%. China had the highest article output (379 papers), whereas the citation rate of papers from the United States was the highest (20,239 citations). The journal "Cancers" had the highest number of publications. Wang J was the most prolific author (35 papers), whereas Diehn M was the most cited author (4460 citations). The five most frequent keywords were "lung cancer" (n = 237), "plasma" (n = 227), "acquired-resistance" (n = 207), "circulating tumor DNA" (n = 177), and "gefitinib" (n = 151).
conclusionThis study provides a comprehensive quantitative synthesis of the ctDNA landscape in lung cancer over the past decade. By identifying key research hotspots and evolutionary trends, our findings offer valuable insights for clinicians and researchers, highlighting the transition of ctDNA from experimental validation to critical translational applications in precision oncology.
Indexed as
Identifiers
41741796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.